ACT MALI: Treatment of Malaria Based on Combination Therapies
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Test the hypothesis that repeated administration of Artesunate/Amiodaquine,
Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of
consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated
falciparum malaria and malaria attributable anemia
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Artemisinins Artesunate Fanasil, pyrimethamine drug combination Lumefantrine Pyrimethamine Sulfadoxine